Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 3, 2011, Pages 184-197

  Gascón, Pere ^a   Aapro, Matti ^b   Ludwig, Heinz ^c   Rosencher, Nadia ^d   Turner, Matthew ^e   Song, MinKyoung ^f,g   MacDonald, Karen ^f   Lee, Christopher ^f,h   Muenzberg, Michael ^e   Abraham, Ivo ^f,h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c WILHELMINEN HOSPITAL   (Austria)

^d Université Paris 5 Descartes ^*  (France)

^e Sandoz Pharma Ltd   (Switzerland)

^f Matrix45 ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

Biosimilars; Chemotherapy induced neutropenia; Febrile neutropenia; Granulocyte colony stimulating factor; Pharmacoepidemiology; Prophylaxis

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CLUSTER ANALYSIS; DATA COLLECTION METHOD; DATA MINING; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; KAPLAN MEIER METHOD; LINEAR SYSTEM; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; POISSON DISTRIBUTION; PRACTICE GUIDELINE; PREDICTION; PROPORTIONAL HAZARDS MODEL; REVIEW; SAMPLE SIZE; STUDY DESIGN; WILCOXON SIGNED RANKS TEST;

CLINICAL TRIALS AS TOPIC; DRUGS, GENERIC; EPIDEMIOLOGIC STUDIES; FILGRASTIM; HUMANS; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 79952172080     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.014     Document Type: Review

References (30)

1. Lalami Y., Paesmans M., Aoun M., et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Supportive Care in Cancer 2004, 12:725-730.
2. Lyman G.H., Lyman C.H., Agboola O. Risk models for predicting chemotherapy-induced neutropenia. The Oncologist 2005, 10:427-437.
3. Kuderer N., Dale D., Crawford J., Cosler L., Lyman G. Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology 2007, 25:3158-3167.
4. Calhoun E., Chang C.H., Welshman E., Cella D. The impact of chemotherapy delays on quality of life in patients with cancer. Journal of Supportive Oncology 2004, 2:64-65.
5. Wingard J.R., Elmongy M. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Critical Reviews in Oncology and Hematology 2009, 10.1016/j.critrevonc.2009.01.003.
6. National Cancer Institute Cancer therapy evaluation program, common toxicity criteria, version 2.0 2009, Last accessed 30 November, 2009. Available from URL:. http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf.
7. Lalami Y., Paesmans M., Muanza F., et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Annals of Oncology 2006, 17:507-514.
8. Crawford J., Dale D., Lyman G.H. Chemotherapy-induced neutropenia. Cancer 2003, 100:228-237.
9. Komorokji R., Lyman G. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapies 2004, 4:1897-1910.
10. Aapro M., Cameron D., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 2006, 42:2433-2453.
11. Gridelli C., Aapro M., Barni S., et al. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Critical Reviews in Oncology and Hematology 2007, 63:53-64.
12. Zielinski C., Awada A., Cameron D., Cufer T., Martin M., Aapro M. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. European Journal of Cancer 2008, 44:353-365.
13. Raposo C.G., Marin A.P., Barón M.G. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clinical Translational Oncology 2006, 8:729-734.
14. Crawford J., Ozer H., Stoller R., et al. Reduction in granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 1991, 325:164-170.
15. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 2006, 29A:319-324.
16. Mangi M.H., Newland A.C. Febrile neutropenia: prophylactic and therapeutic use of GM-CSF. European Journal of Cancer 2000, 35:4-7.
17. Morrison V., Wong M., Hershman D., Campos L., Ding B., Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. Journal of Managed Care Pharmacy 2007, 13:337-348.
18. Smith T., Khatcheressian J., Lyman G., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 24:3187-3205.
19. Lyman G.H. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of evidence. Journal of the National Comprehensive Cancer Network 2005, 3:557-571.
20. Greil R., Jost L.M. ESMO recommendations for the application of hematopoietic growth factors. Annals of Oncology 2005, 16(Suppl. 1):80-82.
21. Klastersky J., Awada A., Aoun M., Paesmans M. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?. Current Opinion in Oncology 2009, 21:297-302.
22. Aapro M., MacDonald K., Van Erps J., et al. Managing cancer-related anemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. European Journal of Cancer 2009, 45:8-11.
23. Last accessed, 30 November, 2009. http://www.emea.europa.eu/humandocs/Humans/EPAR/zarzio/zarzio.htm.
24. Gascón P., Fuhr U., Sörgel F., et al. Development of a new G-CSF product based on biosimilarity assessment. Annals of Oncology 2009, 10.1093/annonc/mdp574.
25. Pettengell R., Bosly A., Szucs T., et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkins lymphoma: data from the INC-EU prospective observational European neutropenia study. British Journal of Haematology 2008, 144:677-685.
26. Hsieh F.Y., Lavori P.W. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Controlled Clinical Trials 2000, 21:552-560.
27. Machin D., Campbell M., Fayers P., Pinol A. Sample size tables for clinical studies 1997, Blackwell Science, Malden, MA. 2nd ed.
28. Nesselroade J.R., Salthouse T.A. Methodological and theoretical implications of intra-individual variability in perceptual-motor performance. Journal of Gerontology: Psychological Science 2004, 59B:49-55.
29. Geller N.L., Pocock S.J. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987, 43:213-223.
30. Schulz K.F., Grimes D.A. Multiplicity in randomised trials II: subgroup and interim analyses. The Lancet 2005, 365:1657-1661.